A Comparison of the Diabetes Risk Score in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) and HAART-Naive Patients at the Limbe Regional Hospital, Cameroon

被引:17
作者
Dimala, Christian Akem [1 ]
Atashili, Julius [2 ]
Mbuagbaw, Josephine C. [2 ]
Wilfred, Akam [2 ]
Monekosso, Gottlieb L. [2 ]
机构
[1] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England
[2] Univ Buea, Fac Hlth Sci, Buea, Cameroon
关键词
HIV-INFECTED PATIENTS; INSULIN SENSITIVITY; PREVALENCE; MELLITUS; TYPE-2; GLUCOSE; METABOLISM; RESISTANCE;
D O I
10.1371/journal.pone.0155560
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Highly active antiretroviral therapy (HAART) has been associated with dysglycaemia. However, there is scarce data on the risk of developing diabetes mellitus (DM) in HIV/AIDS patients in Africa. Objectives Primarily to quantify and compare the risk of having diabetes mellitus in HIV/AIDS patients on HAART and HAART-naive patients in Limbe, Cameroon; and secondarily to determine if there is an association between HAART and increased DM risk. Methods A cross-sectional study was conducted at the Limbe Regional Hospital HIV treatment center between April and June 2013, involving 200 HIV/AIDS patients (100 on first-line HAART regimens for at least 12 months matched by age and gender to 100 HAART-naive patients). The Diabetes Risk Score (DRS) was calculated using a clinically validated model based on routinely recorded primary care parameters. A DRS >= 7% was considered as indicative of an increased risk of developing DM. Results The median DRS was significantly higher in patients on HAART (2.30%) than in HAARTnaive patients (1.62%), p = 0.002. The prevalence of the increased DM risk (DRS >= 7%) was significantly higher in patients on HAART, 31% (95% CI: 22.13-41.03) than in HAART-naive patients, 17% (95% CI: 10.23-25.82), p = 0.020. HAART was significantly associated with an increased DM risk, the odds ratio of the HAART group compared to the HAARTnaive group was 2.19 (95% CI: 1.12-4.30, p = 0.020). However, no association was found after adjusting for BMI-defined overweight, hypertension, age, sex, family history of DM and smoking (Odds ratio = 1.22, 95% CI: 0.42-3.59, p = 0.708). Higher BMI and hypertension accounted for the increased risk of DM in patients on HAART. Also, more than 82% of the participants were receiving or had ever used Zidovudine based HAART regimens. Conclusion HIV/AIDS patients on HAART could be at a greater risk of having DM than HAART-naive patients as a result of the effect of HAART on risk factors of DM such as BMI and blood pressure.
引用
收藏
页数:10
相关论文
共 28 条
[1]   Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs [J].
Araujo, Susana ;
Banon, Sara ;
Machuca, Isabel ;
Moreno, Ana ;
Perez-Elias, Maria J. ;
Casado, Jose L. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 171 (05) :545-554
[2]   Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].
Behrens, G ;
Dejam, A ;
Schmidt, H ;
Balks, HJ ;
Brabant, G ;
Körner, T ;
Stoll, M ;
Schmidt, RE .
AIDS, 1999, 13 (10) :F63-F70
[3]   Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects [J].
Bergersen, BM ;
Sandvik, L ;
Bruun, JN ;
Tonstad, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (08) :625-630
[4]   Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study [J].
Brown, TT ;
Cole, SR ;
Li, XH ;
Kingsley, LA ;
Palella, FJ ;
Riddler, SA ;
Visscher, BR ;
Margolick, JB ;
Dobs, AS .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) :1179-1184
[5]   Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment [J].
Capeau, Jacqueline ;
Bouteloup, Vincent ;
Katlama, Christine ;
Bastard, Jean-Philippe ;
Guiyedi, Vincent ;
Salmon-Ceron, Dominique ;
Protopopescu, Camelia ;
Leport, Catherine ;
Raffi, Francois ;
Chene, Genevieve .
AIDS, 2012, 26 (03) :303-314
[6]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[7]   Effect of Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Dysglycemia and Insulin Sensitivity in South African HIV-Infected Patients [J].
Dave, Joel A. ;
Lambert, Estelle V. ;
Badri, Motasim ;
West, Sacha ;
Maartens, Gary ;
Levitt, Naomi S. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 57 (04) :284-289
[8]   Incidence and risk factors for new-onset diabetes, in HIV-infected patients -: The data collection on adverse events of Anti-HIV drugs (D:A:D) study [J].
De Wit, Stephane ;
Sabin, Caroline A. ;
Weber, Rainer ;
Worm, Signe Westring ;
Reiss, Peter ;
Cazanave, Charles ;
El-Sadr, Wafaa ;
Monforte, Antonella D'Arminio ;
Fontas, Eric ;
Law, Matthew G. ;
Friis-Moller, Nina ;
Phillips, Andrew .
DIABETES CARE, 2008, 31 (06) :1224-1229
[9]   Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naive Patients at the Limbe Regional Hospital, Cameroon [J].
Dimala, Christian Akem ;
Atashili, Julius ;
Mbuagbaw, Josephine C. ;
Wilfred, Akam ;
Monekosso, Gottlieb L. .
PLOS ONE, 2016, 11 (02)
[10]   Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment [J].
Ekali, L. G. ;
Johnstone, L. K. ;
Echouffo-Tcheugui, J. B. ;
Kouanfack, C. ;
Dehayem, M. Y. ;
Fezeu, L. ;
Nouthe, B. ;
Hayes, L. ;
Unwin, N. C. ;
Sobngwi, E. .
DIABETES & METABOLISM, 2013, 39 (01) :71-77